_256_384.jpg)
News | June 19, 2024
Cipla EU to invest an additional € 3 million in Ethris
Cipla had earlier invested € 15 million in Ethris in 2022
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
Subscribe To Our Newsletter & Stay Updated
